Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block

Effect of Adding Dexmedetomidine as Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery. A Prospective Randomized Clinical Trial

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07263165

Acronym

Dexmedetomidin

Enrollment

Registered

2025-12-04

Start date

2025-12-15

Completion date

2027-12-15

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Consumption, Postoperative

Keywords

dexmedetomidine, external oblique intercostal block

Brief summary

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery.

Detailed description

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery. A prospectiverandomized clinical trial

Interventions

DRUGDexmedetomidine

Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients aged 18-70 years scheduled for elective upper abdominal cancer surgery (e.g., gastrectomy, hepatectomy, pancreatectomy). * American Society of Anesthesiologists (ASA) physical status I-III. * Body mass index (BMI) between 18-35 kg/m².

Exclusion criteria

* Patient refusal. * Allergy to local anesthetics or dexmedetomidine. * Coagulopathy (INR \>1.5, platelet count \<100,000/mm³). * Infection at the injection site. * Severe cardiopulmonary, renal, or hepatic dysfunction. * Chronic opioid use (\>30 mg morphine equivalents daily for \>3 months). * Pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame	Description
Total Postoperative Opioid Consumption (mg of morphine equivalents)	24 hours postoperative.	To evaluate the effect of adding dexmedetomidine to bupivacaine on total opioid consumption within the first 24 hours after upper abdominal cancer surgery.

Secondary

Measure	Time frame	Description
Postoperative Pain Intensity Using the Visual Analog Scale (VAS 0-10)	2, 4, 6, 12, 18, and 24 hours postoperative.	Pain scores will be assessed at rest and during movement using the Visual Analog Scale (0 = no pain, 10 = worst pain). Higher scores indicate worse pain.
Time to First Request for Rescue Analgesia.	24 hour postoperative	Time from block performance until first request for analgesia.
Number of Participants with Adverse Effects	first 2 hours postoperative.	Incidence of nausea, vomiting, hypotension, and bradycardia.
patient satisfaction score	1 hour postoperative	Patient satisfaction regarding pain control (0 = completely dissatisfied, 10 = fully satisfied). Higher scores indicate better satisfaction.
Block-related complications.	intraoperative and 24 postoperative	Incidence of hematoma, infection, or local anesthetic systemic toxicity (LAST).

Contacts

Primary ContactMohamed i Shaker

aboiprahem1997@gmail.com01012248619

Backup ContactMoaaz M Tohamy

moaaz@aun.edu.eg

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026